文献速递心力衰竭与心肌病

心力衰竭及其合并症与预期寿命损失的相关性

Association of heart failure and its comorbidities with loss of life expectancy.
PubMed 文献 · Heart · 2020-11-05

本研究为观察性队列研究,纳入1794例左室射血分数降低的稳定慢性心衰患者,随访最长11年(中位5年,999例死亡),采用相对生存框架分析。结果显示心衰患者10年死亡率较年龄性别匹配对照人群额外增加37%(95%CI 34%-40%),相当于额外损失2.2年寿命或2.4倍(2.2-2.5)的超额寿命损失;合并症累积显著增加超额寿命损失,尤其糖尿病、慢性肾脏病和肺部疾病。

要点

  • 心衰患者10年死亡率较对照人群额外增加37%,相当于额外损失2.2年寿命。
  • 男性超额寿命损失大于女性(2.4年 vs 1.6年,p<0.001)。
  • 无合并症女性生存接近对照人群,无合并症男性仍有超额损失。

核心结论

  • 合并症解释了心衰患者大部分预期寿命损失。
  • 无合并症的女性心衰患者生存接近参考对照人群,而男性则不然。

研究设计与样本

  • 观察性队列研究,纳入1794例来自英国四家医院心内科门诊的稳定慢性心衰伴左室射血分数降低的成人患者。
  • 最长随访11年(中位5年),共记录999例死亡,采用相对生存框架与年龄性别匹配的英国对照人群比较。

主要发现

  • 10年后对照人群死亡率为29%,心衰患者额外增加37%(95%CI 34%-40%)。
  • 相当于额外损失2.2年寿命或2.4倍(2.2-2.5)的超额寿命损失。
  • 男性超额损失2.4年(2.2-2.7),女性1.6年(1.2-2.0),p<0.001。
  • 无主要合并症患者中,男性仍有超额损失,女性与对照人群差异无统计学意义(1年(0.6-1.5) vs 0.4年(-0.3至1),p<0.001)。
  • 合并症累积与超额寿命损失大幅增加相关,尤其糖尿病、慢性肾脏病和肺部疾病。

临床怎么用

  • 评估心衰患者预后时应考虑合并症负担对预期寿命的影响。
  • 无合并症的女性心衰患者预后接近一般人群,男性仍需关注超额风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Estimating survival can aid care planning, but the use of absolute survival projections can be challenging for patients and clinicians to contextualise. We aimed to define how heart failure and its major comorbidities contribute to loss of actuarially predicted life expectancy. METHODS: We conducted an observational cohort study of 1794 adults with stable chronic heart failure and reduced left ventricular ejection fraction, recruited from cardiology outpatient departments of four UK hospitals. Data from an 11-year maximum (5-year median) follow-up period (999 deaths) were used to define how heart failure and its major comorbidities impact on survival, relative to an age-sex matched control UK population, using a relative survival framework. RESULTS: After 10 years, mortality in the reference control population was 29%. In people with heart failure, this increased by an additional 37% (95% CI 34% to 40%), equating to an additional 2.2 years of lost life or a 2.4-fold (2.2-2.5) excess loss of life. This excess was greater in men than women (2.4 years (2.2-2.7) vs 1.6 years (1.2-2.0); p<0.001). In patients without major comorbidity, men still experienced excess loss of life, while women experienced less and were non-significantly different from the reference population (1 year (0.6-1.5) vs 0.4 years (-0.3 to 1); p<0.001). Accrual of comorbidity was associated with substantial increases in excess lost life, particularly for diabetes, chronic kidney and lung disease. CONCLUSIONS: Comorbidity accounts for the majority of lost life expectancy in people with heart failure. Women, but not men, without comorbidity experience survival close to reference controls.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Drozd M, Relton SD, Walker AMN, et al. Association of heart failure and its comorbidities with loss of life expectancy. Heart. 2020. PMID: 33153996. doi:10.1136/heartjnl-2020-317833

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。